Item 8.01 Other Events.

On December 4, 2020, bluebird bio, Inc. ("bluebird") and Magenta Therapeutics, Inc. ("Magenta") issued a press release announcing a phase 2 clinical trial collaboration to evaluate the utility of Magenta's MGTA-145 candidate, in combination with plerixafor, for mobilization and collection of stem cells in adults and adolescents with sickle cell disease.

The full text of bluebird's press release regarding the announcement is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits
    Exhibit
      No.                                             Description
     99.1               Press release issued by bluebird bio, Inc. on December 4, 2020.
      104             Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses